Moderna Inc (MRNA)

[Tha Part Time Er]

FDA review clears path for second coronavirus vaccine, this one developed by Moderna
Please Note: The Washington Post is providing this important information about the coronavirus for free. For more free coverage of the coronavirus pandemic, sign up for our Coronavirus Updates newsletter where all stories are free to read.
By the end of the week, the United States could have two coronavirus vaccines.
A vaccine candidate developed by biotechnology company Moderna appears poised for regulatory clearance after a detailed data review by Food and Drug Administration scientists confirmed the two-shot regimen was 94 percent effective in a clinical trial and carried no serious safety concerns.
The 54-page document positions the Moderna vaccine to follow the same historic track as the Pfizer-BioNTech vaccine. After the FDA gave a positive review of the Pfizer-BioNTech vaccine exactly a week ago, the shots were endorsed by a panel of outside experts on Thursday and granted a green light by regulators a day later. The first doses were administered to health care workers on Monday.
Much the same timeline is anticipated this week, given the similar results from Moderna’s vaccine and the fact that it relies on the same underlying technology.
Moderna’s vaccine will be reviewed Thursday by the same panel of independent experts at an all-day public meeting. The data they will consider echoes the evidence that led to a 17 to 4 vote to authorize the Pfizer-BioNTech vaccine, which was 95 percent effective. In addition, the two-shot Moderna regimen was particularly effective against severe disease. There were 30 cases of severe covid-19, the disease caused by the virus, in the trial, none of them in the group that got the vaccine.